A Novel Differentiation Response with Combination IDH Inhibitor and Intensive Induction Therapy for AML

Emily F. Mason, Olga Pozdnyakova, Mikhail Roshal, Amir T. Fathi, Eytan M. Stein, P. Brent Ferrell, Aaron C. Shaver, Mark Frattini, Hongfang Wang, Lei Hua, Jimmy Mu, Sung Choe, Rengyi Xu, Caroline Almon, Michael Cooper, Richard M. Stone, Robert P. Hasserjian, and Michael R. Savona Department of Pathology, Microbiology and Immunology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN; Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN; Celgene Corporation, Summit, NJ; Agios Pharmaceuticals, Inc, Cambridge, MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Program in Cancer Biology and Center for Immunobiology, Vanderbilt University School of Medicine, Nashville, TN